Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex
Year: 2026
Type: article
Abstract: Li reactions, clinical agents like boronophenylalanine (BPA) suffer from excessive dosing and exhibit immune-metabolic inertia. We report a biomineralized albumin-based BNCT agent (Albumin@MnB) synthesized from clinically accessible borax, manganese, and albumin, which unlocks neutron capture-triggered immunotherapeutic activation. Albumin@MnB achieves potent tumor suppression at reduced boron doses, demonstrating superior efficacy compared with BPA. Importantly, Albumin@MnB enhances intratumoral immune cell infiltration and suppresses distant tumor growth, synergizing with adoptive T cell immunotherapy and immune checkpoint inhibitors. By integrating tumor-specific radiolytic energy deposition with metabolic reprogramming and immune activation, this strategy establishes boron neutron capture immunotherapy (BNCI) as a multimodal therapeutic paradigm that bridges targeted radiolysis with systemic antitumor immunity.
Source: Materials Today Bio
Institutions: Institute of Energy, Hefei Comprehensive National Science Center, Soochow University, Nanjing Drum Tower Hospital, First Affiliated Hospital of Soochow University, Nanjing University, University of Science and Technology of China, Dongguan People’s Hospital, Southern Medical University
Language: English
Topic: Boron Compounds in Chemistry
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Funders: Institute of Energy, Hefei Comprehensive National Science Center, National Natural Science Foundation of China, China Postdoctoral Science Foundation, Key Technologies Research and Development Program, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province
OpenAlex ID: W7127892551